Results (3676)
EMA is advising marketing authorisation holders to submit type I variations for 2024 no later than 30 November 2024.
NewsHumanVeterinaryMedicines
Leqembi (lecanemab) recommended for treatment of early Alzheimer’s disease
NewsHumanMedicines
Use of opioid medicines with Mysimba may lead to serious side effects
NewsHumanMedicines
Regulatory update
NewsCorporateMedicines
Re-examination concludes that benefits outweigh risks in a restricted patient population
NewsHumanMedicines
Platform technologies enable rapid response to emerging infectious disease threats
NewsVeterinary
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
NewsVeterinaryMaximum residue limitMedicinesVaccines
PRAC carried out its broad range of responsibilities for managing the risks associated with medicine use
NewsHumanMedicinesPharmacovigilanceReferrals
The European Medicines Agency's (EMA) office is closed on Friday 1 November 2024 for All Saints’ Day.
NewsCorporate
Global regulators discuss available knowledge supporting mpox medicine development and approval
NewsHumanClinical trialsMedicinesVaccines